Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 12/2017

01-12-2017 | Review

The serological markers of acute infection with hepatitis A, B, C, D, E and G viruses revisited

Author: Robério Amorim de Almeida Pondé

Published in: Archives of Virology | Issue 12/2017

Login to get access

Abstract

Viral hepatitis is a liver infection caused by one of the six hepatitis viruses: hepatitis A, B, C, D, E, and G virus (HAV to HEV and HGV). These agents differ in their biological, immunological, pathological and epidemiological characteristics. They cause infections that, when symptomatic, lead to clinical manifestations and laboratory findings that are not specific to a particular virus, often making differential diagnosis difficult, especially when no knowledge is available regarding the patient’s medical history or the epidemiological background. A number of acute-phase serological markers, such as anti-HAV, anti-HBc, anti-HDV and anti-HEV IgM antibodies, are able to provide a clear indication of an infection caused by HAV, HBV, HDV or HEV. Anti-HCV antibodies and HGV/RNA are used for the diagnosis of HCV and HGV infections. The importance of each of these markers will be reviewed, and different factors that can interfere with the diagnosis of acute infections caused by these viruses will be described.
Literature
1.
Nakai K, Win KM, Arakawa Y, Abe K (2001) Molecular characteristic-based epidemiology of hepatitis B, C, and E Viruses and GB Virus C/Hepatitis G Virus in Myanmar. J Clin Microbiol 39(4):1536–1539PubMedPubMedCentralCrossRef
2.
3.
Aggarwal R, Goel A (2015) Hepatitis A: epidemiology in resource-poor countries. Curr Opin Infect Dis. 28(5):488–496PubMedCrossRef
4.
Severi E, Verhoef L, Thornton L, Guzman-Herrador BR, Faber M, Sundqvist L, Rimhanen-Finne R, Roque-Afonso AM (2013) Large and prolonged food-borne multistate hepatitis A outbreak in Europe associated with consumption of frozen berries, 2013 to 2014. Eur Surveill 20(29):21192
5.
Kwon OS, Byun KS, Yeon JE, Park SH, Kim JS, Kim JH, Bak YT, Kim JH, Lee CH (2000) Detection of hepatitis A viral RNA in sera of patients with acute hepatitis A. J Gastroenterol Hepatol 15:1043–1047PubMedCrossRef
6.
Yotsuyanagi H, Koike K, Yasuda K, Moriya K, Shintani Y, Fujie H, Kurokawa K, Iino S (1996) Prolonged fecal excretion of hepatitis A virus in adult patients with hepatitis A as determined by polymerase chain reaction. Hepatology 24:10–13PubMedCrossRef
7.
8.
Cotter S, Sansom S, Long T, Koch E, Kellerman S, Smith F, Averhoff F, Bell BP (2003) Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination strategies. J Infect Dis 187:1235–1240PubMedCrossRef
9.
Leikin E, Lysikiewicz A, Garry D, Tejani N (1996) Intrauterine transmission of hepatitis A virus. Obstet Gynecol. 88:690–691PubMedCrossRef
10.
Erkan T, Kutlu T, Cullu F, Tumay GT (1998) A case of vertical transmission of hepatitis A virus infection. Acta Paediatr 87:1008–1009PubMedCrossRef
11.
Renge RL, Dani VS, Chitambar SD, Arankalle VA (2002) Vertical transmission of hepatitis A. Indian J Pediatr 69:535–536PubMedCrossRef
12.
Schwarz KS, Balistreri WF (2000) Viral hepatitis. In: Pediatric Liver Research Agenda 2000: a blueprint for the future. Developed by the Children’s Liver Council R.J. Sokol, Chair, NJ: American Liver Foundation, pp 56–63
13.
Jacobsen KH, Koopman JS (2005) The effect of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. Int J Epedemiol. 34:600–609CrossRef
14.
Pinheiro R, Araújo L, Caetano K, Matos M, Carneiro M, Teles S (2015) Intermediate endemicity of hepatitis A virus infection in rural settlement projects of southwest Goiás, Brazil. Arq Gastroenterol. 52(3):200–203PubMedCrossRef
15.
16.
Gossner CM, Severi E, Danieisson N, Hutin Y, Coulombier D (2015) Changing hepatitis A epidemiology in the European Union: new challenges and opportunities. Euro Surveill. 20:21101PubMed
17.
Centers for Disease Control and Prevention (1999) Prevention of hepatitis A through active or passive immunization. MMWR Morb Mortal Wkly Rep 48(RR-12), pp 1–37
18.
Sikuler E, Keynan A, Hanuka N (1987) Persistence of a positive test for IgM antibodies to hepatitis A virus in late convalescent sera. Isr J Med Sci 23:193–195PubMed
19.
Centers for Disease Control and Prevention (2005) Positive test results for acute hepatitis A virus infection among persons with no recent history of acute hepatitis—United States, 2002–2004. MMWR Morb Mortal Wkly Rep 54:453–456
20.
Castrodale L, Fiore A, Schmidt T (2005) Detection of immunoglobulin M antibody to hepatitis A virus in Alaska residents without other evidence of hepatitis. Clin Infect Dis 41:e86–e88PubMedCrossRef
21.
Hyun J, Seo YS, An H, Yim SY, Seo MH, Kim HS, Kim CH, Kim JH, Keum B, Kim YS, Yim HJ, Lee HS, Um SH, Kim CD, Ryu HS (2012) Optimal time for repeating the IgM anti-hepatitis A virus antibody test in acute hepatitis A patients with a negative initial test. Korean J Hepatol 18(1):56–62. doi:10.​3350/​kjhep.​2012.​18.​1.​56 PubMedPubMedCentralCrossRef
22.
Bower WA, Nainan OV, Han X, Margolis H (2000) Duration of viremia in hepatitis A virus infection. J Infect Dis 182:12–17PubMedCrossRef
23.
Shin HP, Lee JI, Jung SW, Cha JM, Joo KR, Kang SY (2010) Factors for predicting positive results for anti-HAV IgM retesting among initially seronegative patients. Dig Dis Sci. 55(12):3537–3540PubMedCrossRef
24.
Petrov P, Nikolova A, Komitova R, et al (2007) Acute hepatitis A infection with negative anti-HAV IgM. In: Global Hepatitis A Meeting Program. p 137
25.
Arcangeletti M, Dussaix E, Ferraglia A, Roque-Afonso A, Graube A, Chezzi C (2011) Multicentric evaluation of new commercial enzyme immunoassays for the detection of immunoglobulin M and total antibodies against hepatitis A virus. Clin Vaccine Immunol 18(8):1391–1394PubMedPubMedCentralCrossRef
26.
Park H, Lee YJ, Seong MW, Lee DH, Park MH, Song EY (2013) Comparison of 3 automated immunoassays for detection of anti-hepatitis A virus immunoglobulin M in a tertiary care hospital. Ann Lab Med 33(2):121–124PubMedPubMedCentralCrossRef
27.
Roque-Afonso AM, Mackiewicz V, Dussaix E (2006) Detection of immunoglobulin M antibody to hepatitis A virus in patients without acute hepatitis A: the usefulness of specific immunoglobulin G avidity. Clin Infect Dis 42:887–888PubMedCrossRef
28.
Sacher RA, Peters SM, Bryan JÁ (2000) Testing for viral hepatitis: a practice parameter. Am J Clin Pathol 113(1):12–17PubMedCrossRef
29.
Alatoom A, Ansari MQ, Cuthbert J (2013) Multiple factors contribute to positive results for hepatitis A virus immunoglobulin M antibody. Arch Pathol Lab Med 137(1):90–95PubMedCrossRef
30.
Castaneda-Ibarra F, Ruiz-Maya L, Campos- Rodriguez R, Garcia Latorre E (1991) Polyclonal activation of B lymphocytes in patients with amoebic hepatic abscess. Arch Invest Med (Mex) 22:13–17
31.
Aalto SM, Linnavuori K, Peltola H et al (1998) Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol 56:186–191PubMedCrossRef
32.
Nobutoki T, Hori H, Higashigawa M et al (1996) A case of prolonged human parvovirus B19DNAemia associated with polyclonal B cell activation. Acta Paediatr Jpn 38:348–351PubMedCrossRef
33.
Yang NY, Yu PH, Mao ZX, Chen NL, Chai SA, Mao JS (1988) Inapparent infection of hepatitis A virus. Am J Epidemiol 127:599–604PubMedCrossRef
34.
Chakvetadze C, Mallet V, Gaussec L, Hannoun L, Pol S (2011) Acute hepatitis A virus infection without IgM antibodies to hepatitis A virus. Ann Intern Med 154(7):507–508PubMedCrossRef
35.
Hou J, Liu Z, Gu F (2005) Epidemiology and prevention of hepatitis B virus infection. Int J Med 43(3):187–190
36.
Ali BA, Huang TH, Salem HH, Xie QD (2006) Expression of hepatitis B virus genes in early embryonic cells originated from hamster ova and human spermatozoa transfected with the complete viral genome. Asian J Androl 8:273–279PubMedCrossRef
37.
Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ (1996) The risk of transfusion-transmitted viral infections. N Engl J Med 334:1685–1690PubMedCrossRef
38.
Grant P, Busch M (2002) Nucleic acid amplification technology methods used in blood donor screening. Transfus Med 12:229–242PubMedCrossRef
39.
Scheiblauer H, El-Nageh M, Diaz S, Nick S, Zeichhard H, Grunert H-P, Prince A (2010) Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes. Vox Sang 98(3p2):403–414PubMedPubMedCentralCrossRef
40.
Pondé R (2013) Atypical serological profile in hepatitis B infection. Eur Clin Microbiol and Infect Dis 32(4):461–476CrossRef
41.
Kao JH (2008) Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol 2(4):553–562PubMedCrossRef
42.
Gerlich WH, Lüer W, Thomssen R (1980) Diagnosis of acute and inapparent hepatitis B virus infections by measurement of IgM antibody to hepatitis B core antigen. J Infect Dis 142(1):95–101PubMedCrossRef
43.
Cappel R, van Beers D, Maes F, Toppet M, Cadravel S (1981) Significance of persisting IgM anti-HBc antibodies in hepatitis B vírus infections. J Med Virol 8(3):201–205PubMedCrossRef
44.
Milich DR, McLachlan A (1986) The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234:1398–1401PubMedCrossRef
45.
Pondé R (2016) Acute hepatitis B virus infection or acute exacerbation of chronic hepatitis B infection: The differential diagnosis. Eur Clin Microbiol and Infect Dis 35(1):29–40CrossRef
46.
Lemon SM, Gates NL, Simms TE, Bancroft WH (1981) IgM antibody to hepatitis B core antigen as a diagnostic parameter of acute infection with hepatitis B virus. J Infect Dis 143:803–809PubMedCrossRef
47.
Gerlich WH, Uy A, Lambrecht F, Thomssen R (1986) Cutoff levels of immunoglobulin IgM antibody against viral core antigen for differentiation of acute, chronic, and past hepatitis B virus infections. J Clin Microbiol 24:288–293PubMedPubMedCentral
48.
Hadziyannis E, Manesis E, Vassilopoulos D, Georgiou A, Archimandritis A (2008) Performance characteristics of microparticle enzyme and chemiluminescence immunoassays for measurement of anti-HBc immunoglobulin M in sera of patients with HBeAg-negative chronic hepatitis B virus Infection. Clin Vaccine Immunol 15(2):385–387PubMedCrossRef
49.
Chen D, Kaplan L, Qiang Liu Q (2005) Evaluation of two chemiluminescent immunoassays of ADVIA centaur for hepatitis B serology markers. Clinica Chimica Acta 355:41–45CrossRef
50.
van Helden J, Denoyel G, Karwowska S, Reamer R, Schmalz J, Wright T, Preisel-Simmons B (2004) Performance of hepatitis B assays on the Bayer ADVIA Centaur Immunoassay System. Clin Lab. 50(1–2):63–73PubMed
51.
52.
Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH (2012) Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 55(1):68–76PubMedCrossRef
53.
Chan HL, Wong GL, Tse CH, Chan HY, Wong VW (2011) Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 204(3):408–414PubMedCrossRef
54.
Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M, Chisari FV (2010) Immune effectors required for hepatitis B vírus clearance. Proc Natl Acad Sci U S A 107(2):798–802PubMedCrossRef
55.
Jeremiah ZA, Idris H, Ajayi BB, Ezimah AC, Malah MB, Baba MM (2011) Isolated anti-Hbc-IgM antibody among blood donors in the semi-arid region of Nigéria. Hum Antibodies 20(3–4):77–82PubMed
56.
Japhet M, Adesina O, Donbraye E, Adewumi M (2011) Hepatitis B Core IgM antibody (anti-HBcIgM) among Hepatitis B Surface antigen (HBsAg) negative blood donors in Nigeria. Virol J 8:513PubMedPubMedCentralCrossRef
57.
Pondé R (2011) The underlying mechanisms for the isolated positivity for the hepatitis B surface antigen (HBsAg) serological profile. Med Microbiol Immunol 200(1):13–22PubMedCrossRef
58.
Irving W, Salmon D, Boucher C, Hoepelman I (2008) Acute hepatitis C virus infection. EuroSurveill 13(21):1–4
59.
60.
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333–1342PubMedCrossRef
61.
Lau GK, Lesniewski R, Johnson RG, Davis GL, Lau JY (1994) Immunoglobulin M and A antibodies to hepatitis C core antigen in chronic hepatitis C virus infection. J Med Virol 44:1–4PubMedCrossRef
62.
Pawlotsky JM, Darthuy F, Remire J, Pellet C, Udin L, Stuyver L, Roudot-Thoraval F, Duvoux C, Douvin C, Mallat A et al (1995) Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C. J Med Virol 47:285–291PubMedCrossRef
63.
Sagnelli E, Coppola N, Marrocco C, Coviello G, Rossi G, Battaglia M, Sagnelli C, Messina V, Tonziello A, Scolastico C, Filippini P (2003) Diagnosis of HCV related acute hepatitis by serial determination of IgM to HCV: a preliminary observation. J Biol Regul Homeost Agents 17:207–210PubMed
64.
Yuki N, Hayashi N, Ohkawa K, Hagiwara H, Oshita M, Katayama K, Sasaki Y, Kasahara A, Fusamoto H, Kamada T (1995) The significance of immunoglobulin M antibody response to hepatitis C virus core protein in patients with chronic hepatitis C. Hepatology 22:402–406PubMed
65.
Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, Feinstone SM, Alter H, Rice CM, McKeating JÁ (2004) Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 101:10149–10154PubMedPubMedCentralCrossRef
66.
Nikolaeva LI, Blokhina NP, Tsurikova NN, Voronkova NV, Miminoshvili MI, Braginsky DM, Yastrebova ON, Booynitskaya OB, Isaeva OV, Michailov MI, Archakov AI (2002) Virus-specific antibody titres in different phases of hepatitis C virus infection. J Viral Hepat 9:429–437PubMedCrossRef
67.
Kamili S, Drobeniuc J, Araujo AC, Hayden TM (2012) Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis 55(Suppl1):S43–S48PubMedCrossRef
68.
Kesli R (2012) An Overview of the laboratory assay systems and reactives used in the diagnosis of hepatitis C virus (HCV) infections. In: Abuelzein E (ed) Trends in immunolabelled and related techniques. Rijeka, InTech, pp 340–350
69.
Irshad M, Mankotia DS, Irshad K (2013) An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol 19(44):7896–7909PubMedPubMedCentralCrossRef
70.
Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C (2001) Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 8:87–95PubMedCrossRef
71.
Uliana CV, Riccardi CS, Yamanaka H (2014) Diagnostic tests for hepatitis C: recent trends in electrochemical immunosensor and genosensor analysis. World J Gastroenterol 20:15476–15491PubMedPubMedCentralCrossRef
72.
Villar LM, Cruz HM, Barbosa JR, Bezerra CS, Portilho MM, Scalioni Lde P (2015) Update on hepatitis B and C virus diagnosis. World J Virol 4(4):323–342PubMedPubMedCentral
73.
Alborino F, Burighel A, Tiller FW, van Helden J, Gabriel C, Raineri A, Catapano R, Stekel H (2011) Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity. Med Microbiol Immunol 200(2):77–83PubMedCrossRef
74.
Seignères B, Descamps F, Croise R, Barlet V, Bouvier-Alias M, Chevaliez S, Pawlotsky JM, Abdelhady W, Rafik M, Avellon AM, Echevarria JM, Hausmann M, Dugua JM (2016) Multicenter clinical evaluation of the new 3rd generation assay for detection of antibodies against hepatitis C virus on the VIDAS(®) system. J Clin Virol 78:20–26PubMedCrossRef
75.
Yoo SJ, Wang LL, Ning HC, Tao CM, Hirankarn N, Kuakarn S, Yang R, Han TH, Chan RC, Hussain BM, Hussin H, Muliaty D, Shen L, Liu H, Wei L (2015) Evaluation of the Elecsys(®) Anti-HCV II assay for routine hepatitis C virus screening of different Asian Pacific populations and detection of early infection. J Clin Virol 64:20–27PubMedCrossRef
76.
Ré V, Gallego S, Trevino E, Barbas G, Dominguez C, Elbarcha O, Bepre H, Contigiani M (2005) Evaluation of five screening tests licensed in Argentina for detection of hepatitis C virus antibodies. Mem Inst Oswaldo Cruz 100(3):303–307PubMedCrossRef
77.
Scheiblauer H, El-Nageh M, Nick S, Fields H, Prince A, Diaz S (2006) Evaluation of the performance of 44 assays used in countries with limited resources for the detection of antibodies to hepatitis C virus. Transfusion 46(5):708–718PubMedCrossRef
78.
Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335–1374PubMedCrossRef
79.
Pondé R (2013) Enzyme-linked immunosorbent/chemiluminescence assays, recombinant immunoblot assays and nucleic acid tests in the diagnosis of HCV infection. Eur J Clin Microbiol Infect Dis 32(8):985–988PubMedCrossRef
80.
Vo MT, Bruhn R, Kaidarova Z, Custer BS, Murphy EL, Bloch EM (2016) A retrospective analysis of false-positive infectious screening results in blood donors. Transfusion 56(2):457–465PubMedCrossRef
81.
Hajarizadeh B, Grebely J, Dore GJ (2012) Case definitions for acute hepatitis C virus infection: a systematic review. J Hepatol 57(6):1349–1360PubMedCrossRef
82.
Molmenti E, Klintmalm G (2000) Hepatitis C recurrence after liver transplantation. Liver Transpl 6(4):413–414PubMedCrossRef
83.
Chen J, Chung J, Kao J, Chen D (2001) Post-partum acute exacerbation of chronic hepatitis in a hepatitis C-carrier mother. J Gastroenterol Hepatol 16(6):705–708PubMedCrossRef
84.
Vento S, Cainelli F, Longhi M (2002) Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: na unresolved issue. Lancet Oncol 3(6):333–340PubMedCrossRef
85.
Melon S, Galarraga M, Villar M, Laures A, Boga J, de Oña M, Gomez E (2005) Hepatitis C vírus reactivation in anti-hepatitic C virus-positive renal transplant recipients. Transpl Proc 37(5):2083–2085CrossRef
86.
Ennishi D, Yokoyama M, Terui Y, Takeuchi K, Ikeda K, Tanimoto M, Hatake K (2008) Does rituximab really induce hepatitis C virus reactivation? J Clin Oncol 26(28):4695–4696PubMedCrossRef
87.
Irving W, Salmon D, Boucher C, Hoepelman I (2008) Acute hepatitis C virus infection. EuroSurveill 13(21):1–4
88.
Sagnelli E, Sagnelli C, Pisaturo M, Coppola N (2014) Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection. World J Gastroenterol 20(22):6707–6715PubMedPubMedCentralCrossRef
89.
Kondili LA, Chionne P, Costantino A, Villano U, Lo Noce C, Pannozzo F, Mele A, Giampaoli S, Rapicetta M (2002) Infection rate and spontaneous seroconversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut 50(5):693–696PubMedPubMedCentralCrossRef
90.
Kee KM, Wang JH, Hung CH et al (2012) Decreased anti-HCV titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study. J Gastroenterol Hepatol 27:1106–1111PubMedCrossRef
91.
Coppola N, Pisapia R, Marrocco C, Martini S, Vatiero LM, Messina V, Tonziello G, Sagnelli C, Filippini P, Piccinino F, Sagnelli E (2007) Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 40(2):110–115PubMedCrossRef
92.
Sagnelli E, Tonziello G, Pisaturo M, Sagnelli C, Coppola N (2012) Clinical applications of antibody avidity and immunoglobulin M testing in acute HCV infection. Antivir Ther 17(7ptB):1453–1458PubMedCrossRef
93.
Rizzetto M, Ponzetto A, Forzani I (1990) Hepatitis delta virus as a global health problem. Vaccine 8:S10–S14 (discussion S21-13) PubMedCrossRef
94.
95.
96.
97.
98.
Borghesio E, Rosina F, Smedile A, Lagget M, Niro MG et al (1998) Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. Hepatology 27:873–876PubMedCrossRef
99.
Farci P, Gerin JL, Aragona M, Lindsey I, Crivelli O et al (1986) Diagnostic and prognostic significance of the IgM antibody to the hepatitis delta virus. JAMA 255:1443–1446PubMedCrossRef
100.
Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Manns MP, Wedemeyer H, Hep-Net/International Delta Hepatitis Study Group (2012) Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment. Antivir Ther 17(2):305–312PubMedCrossRef
101.
Brichler S, Le Gal F, Butt A, Chevret S, Gordien E (2013) Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify delta virus viremia. Clin Gastroenterol Hepatol 11:734–740PubMedCrossRef
102.
Hofmann J, Frenzel K, Minh BQ, von Haeseler A, Edelmann A, Ross SR, Berg T, Kruger DH, Meisel H (2010) Quantitative detection and typing of hepatitisDvirus in human serum by real-time polymerase chain reaction and melting curve analysis. Diagn Microbiol Infect Dis 67:172–179PubMedCrossRef
103.
Mederacke I, Bremer B, Heidrich B, Kirschner J, Deterding K, Bock T, Wursthorn K, Manns MP, Wedemeyer H (2010) Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 48:2022–2029PubMedPubMedCentralCrossRef
104.
105.
Brichler S, Le Gal F, Neri-Pinto F, Mansour W, Roulot D, Laperche S, Gordien E (2014) Serological and molecular diagnosis of hepatitis delta virus infection: results of a French national quality control study. J Clin Microbiol 52(5):1694–1697PubMedPubMedCentralCrossRef
106.
Kodani M, Martin A, Mixson-Hayden T et al (2013) One-step real-time PCR assay for detection and quantitation of hepatitis D virus RNA. J Virol Methods 193:531–535PubMedCrossRef
107.
Yarbough PO, Tam AW, Fry KE, Krawczynski K, McCaustland KA, Bradley DW, Reyes GR (1991) Hepatitis E virus: identification of type-common epitopes. J Virol 65:5790–5797PubMedPubMedCentral
108.
109.
110.
111.
112.
113.
Mast EE, Alter MJ, Holland PV, Purcell RH (1998) Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatology 27:857–861PubMedCrossRef
114.
Drobeniuc J, Meng J, Reuter G, Greene-Montfort T, Khudyakova N, Dimitrova Z, Kamili S, Teo CG (2010) Serologic assays specific to immunoglobuilin M antibodies against hepatitis E virus: pangenotypic evaluation of performance. Clin Infect Dis 51(3):e24–e27PubMedCrossRef
115.
Lin C-C, Wu JC, Chang TT, Chang WY, Yu ML, Tam AW, Wang SC, Huang YH, Chang FY, Lee SD (2000) Diagnostic value of immunoglobulin G (IgG) and IgM anti-hepatitis E virus (HEV) tests based on HEV RNA in an area where hepatitis E is not endemic. J Clin Microbiol 38(11):3915–3918PubMedPubMedCentral
116.
Seriwatana J, Shrestha MP, Scott RM et al (2002) Clinical and epidemiological relevance of quantitating hepatitis E virus-specific immunoglobulin M. Clin Diagn Lab Immunol 9:1072–1078PubMedPubMedCentral
117.
Yu C, Engle RE, Bryan JP, Emerson SU, Purcell RH (2003) Detection of immunoglobulin M antibodies to hepatitis E virus by class capture enzyme immunoassay. Clin Diagn Lab Immunol 10:579–586PubMedPubMedCentral
118.
Pas SD, Streefkerk RH, Pronk M, de Man RA, Beersma MF, Osterhaus AD, van der Eijk AA (2013) Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. J Clin Virol 58(4):629–634PubMedCrossRef
119.
Abravanel F, Chapuy-Regaud S, Lhomme S, Miedougé M, Peron JM, Alric L, Rostaing L, Kamar N, Izopet J (2013) Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. J Clin Virol 58(4):624–628PubMedCrossRef
120.
Koshy A, Grover S, Hyams KC, Shabrawy MA, Pacsa A, Al-Nakib B, Zaidi SA, Al-Anezi AA, Al-Mufti S, Burans J, Carl M, Richards AL (1996) Short-term IgM and IgG antibody response to hepatitis E virus infection. Scand J Infect Dis 28:439–441PubMedCrossRef
121.
Inagaki Y, Oshiro Y, Imanishi M, Ishige K, Takahashi M, Okamoto H, Ohkohchi N (2015) Acute infection by hepatitis E virus with a slight immunoglobulin M antibody response. Clin J Gastroenterol 8(4):247–252PubMedCrossRef
122.
123.
Aggarwal R, Kini D, Sofat S, Naik SR, Krawczynski K (2000) Duration of viraemia and faecal viral excretion in acute hepatitis E. Lancet 356:1081–1082PubMedCrossRef
124.
Purcell RH, Emerson SU (2008) Hepatitis E: an emerging awareness of an old disease. J Hepatol 48:494–503PubMedCrossRef
125.
Dalton HR, Bendall R, Ijaz S, Banks M (2008) Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 8:698–709PubMedCrossRef
126.
Simons JN, Pilot-Matias TJ, Leary TP, Dawson GJ, Desai SM, Schlauder GG, Muerhoff AS, Erker JC, Buijk SL, Chalmers ML (1995) Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci USA 92:3401–3405PubMedPubMedCentralCrossRef
127.
Linnen J, Wages J Jr, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, Koonin E, Gallagher M, Alter M, Hadziyannis S, Karayiannis P, Fung K, Nakatsuji Y, Shih JW, Young L, Piatak M Jr, Hoover C, Fernandez J, Chen S, Zou JC, Morris T, Hyams KC, Ismay S, Lifson JD, Hess G, Foung SK, Thomas H, Bradley D, Margolis H, Kim JP (1996) Molecular cloning and disease association of hepatitis G virus: a transfusiontransmissible agent. Science 271:505–508PubMedCrossRef
128.
129.
Wiwanitkit V (2005) Hepatitis G virus RNA positivity among the voluntary blood donors: a summary. Ann Hepatol 4:43–46PubMed
130.
Kachko AV, Ershov AE, Gavrilova IV, Shustov AV, Kochneva GV, Sivolobova GF, Grazhdantseva AA, Bukin VN, Komissarova MA, Netesov SV (2005) The occurrence rate of HGV/GBV-C RNA and risk factors in patients of narcological dispensary in Novosibirsk. Zh Mikrobiol Epidemiol Immunobiol 2:25–30
131.
Karayiannis P, Pickering J, Chiaramonte M, Thomas HC (1997) Hepatitis G virus infection. Lancet 349:954PubMedCrossRef
132.
Rubio A, Rey C, Sanchez-Quijano A, Leal M, Pineda JA, Lissen E, Hess G (1997) Is hepatitis G virus transmitted sexually? JAMA 277:532–533PubMedCrossRef
133.
Yeo AE, Matsumoto A, Shih JW, Alter HJ, Goedert JJ (2000) Prevalence of hepatitis G virus in patients with hemofilia and their steady female sexual partners. Sex Transm Dis 27:178–182PubMedCrossRef
134.
Ohto H, Ujiie N, Sato A, Okamoto H, Mayumi M (2000) Mother-to-infant transmission of GB virus type C/HGV. Transfusion 40:725–730PubMedCrossRef
135.
136.
Feng Y, Liu L, Feng YM, Zhao W, Li Z, Zhang AM, Song Y, Xia X (2014) GB virus C infection in patients with HIV/hepatitis C virus coinfection: improvement of the liver function in chronic hepatitis C. Hepat Mon 14(3):e14169PubMedPubMedCentralCrossRef
137.
138.
Liu H, Mao P, Hong S (1999) Detection of IgM-antibody to hepatitis G virus and its clinical significance. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 13(1):77–79PubMed
139.
Tacke M, Kiyosawa K, Stark K, Schlueter V, Ofenloch-Haehnle B, Hess G et al (1997) Detection of antibodies to a putative hepatitis G virus envelope protein. Lancet 349:318–320PubMedCrossRef
140.
Tan D, Matsumoto A, Conry-Cantilena C, Melpolder JC, Shih JW, Leuther M et al (1999) Analysis of hepatitis G virus (HGV) RNA, antibody to HGV envelope protein, and risk factors for blood donors co-infected with HGV and hepatitis C virus. J Infect Dis 179:1055–1061PubMedCrossRef
141.
Lo SY, Ku CW, Ma HC, Li YH, Yu JH, Lin HH, Lua AC, Lee ML (2002) Detection of serologic responses to GB virus C/hepatitis G virus infection. Int J Infect Dis 6(3):223–227PubMedCrossRef
142.
Ramezani A, Gachkar L, Eslamifar A, Khoshbaten M, Jalilvand S, Adibi L, Salimi V, Hamkar R (2008) Detection of hepatitis G virus envelope protein E2 antibody in blood donors. Int J Infect Dis 12:57–61PubMedCrossRef
143.
Lefrere JJ, Loiseau P, Maury J, Lasserre J, Mariotti M, Ravera N et al (1997) Natural history of GB virus C/hepatitis G virus infection through follow up of GBV-C hepatitis G virus infected blood donors and recipients studied by RNA polymerase chain reaction and anti-E2 serology. Blood 90:3776–3780PubMed
144.
Kao JH, Chen W, Chen PJ, Lai MY, Chen DS (1999) Liver and peripheral blood mononuclear cells are not major sites for GB virus-C/hepatitis G virus replication. Arch Virol 144:2173–2183PubMedCrossRef
145.
Handa A, Brown KE (2000) GB virus C/hepatitis G virus replicates in human haematopoietic cells and vascular endothelial cells. J Gen Virol 81:2461–2469PubMedCrossRef
146.
Pessoa MG, Terrault NA, Detmer J, Kolberg J, Collins M, Hassoba HM, Wright TL (1998) Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology 27:877–880PubMedCrossRef
147.
Berg T, Muller AR, Platz KP, Hohne M, Bechstein WO, Hopf U, Wiedenmann B, Neuhaus P, Schreier E (1999) Dynamics of GB virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication. Hepatology 29:245–249PubMedCrossRef
Metadata
Title
The serological markers of acute infection with hepatitis A, B, C, D, E and G viruses revisited
Author
Robério Amorim de Almeida Pondé
Publication date
01-12-2017
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 12/2017
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-017-3538-3

Other articles of this Issue 12/2017

Archives of Virology 12/2017 Go to the issue

Annotated Sequence Record

Characterization of a novel botybirnavirus isolated from a phytopathogenic Alternaria fungus

Original Article

Molecular characterization of atypical antigenic variants of canine rabies virus reveals its reintroduction by wildlife vectors in southeastern Mexico

Original Article

Molecular evolution and epidemiological links study of Newcastle disease virus isolates from 1995 to 2016 in Iran

Original Article

A resequencing pathogen microarray method for high-throughput molecular diagnosis of multiple etiologies associated with central nervous system infection

Original Article

Molecular characterization of very virulent infectious bursal disease virus strains circulating in Egypt from 2003 to 2014

Original Article

A measles outbreak in Sindh, Pakistan caused by a genotype B3 virus

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits